Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.

Date publication

janvier 2024

Journal

NEJM evidence

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Fizazi K, Bernard-Tessier A, Roubaud G, Utriainen T, Barthélémy P, Fléchon A, van der Voet J, Gravis G, Ratta R, Jones R, Parikh O, Tanner M, Antonarakis ES, Baldini C, Peters N, Garratt C, Ikonen T, Pohjanjousi P, Joensuu H, Cook N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38320513

Résumé

Targeted Inhibition of CYP11A1 in Prostate CancerIn this single-arm, multicenter, combined phase 1 and phase 2 study, patients with metastatic prostate adenocarcinoma with progression on prior androgen receptor pathway inhibitors and taxane-based chemotherapy were treated with ODM-208. A decrease in prostate-specific antigen levels of 50% or more occurred in 16/42 (38.1%) and 24/45 (53.3%) in phase 1 and 2 respectively. Responses mainly occurred in patients with androgen receptor mutations. Adrenal insufficiency was the dose-limiting toxicity.

Mots clés

Male, Humans, Receptors, Androgen, therapeutic use, Prostatic Neoplasms, Castration-Resistant, drug therapy, Cholesterol Side-Chain Cleavage Enzyme, Prostate-Specific Antigen, therapeutic use, Treatment Outcome, Androgen Receptor Antagonists, pharmacology

Référence

NEJM Evid. 2024 01;3(1):EVIDoa2300171